Agilon Health shares surge 115% after earnings beat and outlook upgrade
Updated
Updated · Barron's · May 7
Agilon Health shares surge 115% after earnings beat and outlook upgrade
11 articles · Updated · Barron's · May 7
The stock jumped to $60.01 on Thursday after first-quarter revenue of $1.42bn beat forecasts and adjusted EBITDA rose to $54m from $21m, far above the $37m consensus.
Agilon now targets full-year adjusted EBITDA of $25m at the midpoint, versus expectations for a $12m loss, helped by strong ACO REACH performance and better visibility into healthcare costs.
Jefferies and Deutsche Bank upgraded the stock, but Agilon still faces investor lawsuits and remains down nearly 28% over 12 months after a 64% slump in 2025.
After its stock surged 115%, can Agilon's profit-first strategy survive looming lawsuits and major regulatory changes?
Agilon credits its turnaround to AI and data. What is the tech secret behind its record-breaking financial recovery?